Yan Fu
Yan Fu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Fanglin Liu
Center for Traditional Chinese Medicine and Immunology Research
2 shared publicationsJingjing Shen
Center for Traditional Chinese Medicine and Immunology Research
2 shared publications- Xin Jiang
Shanghai University of Traditional Chinese Medicine
2 shared publications - Yuejuan Zheng
The Research Center for Traditional Chinese Medicine, Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publications Bangzuo Ning
Center for Traditional Chinese Medicine and Immunology Research
1 shared publicationHemin Zhang
Center for Traditional Chinese Medicine and Immunology Research
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1885066
Andrographolide Suppresses Pyroptosis in Mycobacterium tuberculosis-Infected Macrophages via the microRNA‐155/Nrf2 Axis
Tuberculosis (TB) remains a leading threat to public health worldwide with Mycobacterium tuberculosis (Mtb) infections causing long‐term abnormal and excessive inflammatory responses, which in turn lead to lung damage and fibrosis, and ultimately death. Host‐directed therapy (HDT) has been shown to be an effective anti‐TB strategy in the absence of effective anti‐TB drugs. Here, we used an in vitro macrophage model of Mtb infection to evaluate the effects of andrographolide (Andro), extracted from Andrographis paniculata, on pyroptosis in Mtb‐infected macrophages. We evaluated the molecular mechanisms underlying these outcomes. These evaluations revealed that Andro downregulated the expression of proinflammatory miR‐155‐5p, which then promoted the expression of Nrf2 to suppress pyroptosis in Mtb‐infected macrophages. Further study also demonstrated that siNrf2 could attenuate the inhibitory effect of Andro on TXNIP, validating our mechanistic studies. Thus, our data suggest that Andro may be a potential candidate adjuvant drug for anti‐TB therapy as it inhibits pyroptosis in Mtb‐infected macrophages, potentially improving clinical outcomes.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1885066
Open AccessAndrographolide Suppresses Pyroptosis in Mycobacterium tuberculosis-Infected Macrophages via the microRNA‐155/Nrf2 Axis
Tuberculosis (TB) remains a leading threat to public health worldwide with Mycobacterium tuberculosis (Mtb) infections causing long‐term abnormal and excessive inflammatory responses, which in turn lead to lung damage and fibrosis, and ultimately death. Host‐directed therapy (HDT) has been shown to be an effective anti‐TB strategy in the absence of effective anti‐TB drugs. Here, we used an in vitro macrophage model of Mtb infection to evaluate the effects of andrographolide (Andro), extracted from Andrographis paniculata, on pyroptosis in Mtb‐infected macrophages. We evaluated the molecular mechanisms underlying these outcomes. These evaluations revealed that Andro downregulated the expression of proinflammatory miR‐155‐5p, which then promoted the expression of Nrf2 to suppress pyroptosis in Mtb‐infected macrophages. Further study also demonstrated that siNrf2 could attenuate the inhibitory effect of Andro on TXNIP, validating our mechanistic studies. Thus, our data suggest that Andro may be a potential candidate adjuvant drug for anti‐TB therapy as it inhibits pyroptosis in Mtb‐infected macrophages, potentially improving clinical outcomes.
- Open Access
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Inhibition of the PERK/TXNIP/NLRP3 Axis by Baicalin Reduces NLRP3 Inflammasome‐Mediated Pyroptosis in Macrophages Infected with Mycobacterium tuberculosis
Mycobacterium tuberculosis (Mtb) remains a significant threat to global health as it induces granuloma and systemic inflammatory responses during active tuberculosis. Mtb can induce macrophage pyroptosis, leading to the release of IL‐1β and tissue damage, promoting its spread. Here, we established an in vitro Mtb‐infected macrophage model to seek an effective antipyroptosis agent. Baicalin, isolated from Radix Scutellariae, was found to reduce pyroptosis in Mtb‐infected macrophages. Baicalin could inhibit activation of the PERK/eIF2α pathway and thus downregulates TXNIP expression and subsequently reduces activation of the NLRP3 inflammasome, resulting in reduced pyroptosis in Mtb‐infected macrophages. In conclusion, baicalin reduced pyroptosis by inhibiting the PERK/TXNIP/NLRP3 axis and might thus be a new adjuvant host‐directed therapy (HDT) drug.
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Open AccessInhibition of the PERK/TXNIP/NLRP3 Axis by Baicalin Reduces NLRP3 Inflammasome‐Mediated Pyroptosis in Macrophages Infected with Mycobacterium tuberculosis
Mycobacterium tuberculosis (Mtb) remains a significant threat to global health as it induces granuloma and systemic inflammatory responses during active tuberculosis. Mtb can induce macrophage pyroptosis, leading to the release of IL‐1β and tissue damage, promoting its spread. Here, we established an in vitro Mtb‐infected macrophage model to seek an effective antipyroptosis agent. Baicalin, isolated from Radix Scutellariae, was found to reduce pyroptosis in Mtb‐infected macrophages. Baicalin could inhibit activation of the PERK/eIF2α pathway and thus downregulates TXNIP expression and subsequently reduces activation of the NLRP3 inflammasome, resulting in reduced pyroptosis in Mtb‐infected macrophages. In conclusion, baicalin reduced pyroptosis by inhibiting the PERK/TXNIP/NLRP3 axis and might thus be a new adjuvant host‐directed therapy (HDT) drug.